The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?

Barberio, Brigida; Zingone, Fabiana; Bertani, Lorenzo; Savarino, Edoardo

Barberio, Brigida; Zingone, Fabiana; Bertani, Lorenzo; Savarino, Edoardo.

Barberio B; Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Zingone F; Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Bertani L; Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Savarino E; Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.

Gastroenterology ; 160(5): 1903-1904, 2021 04.

Article in English | MEDLINE | ID: covidwho-650340

Subject(s)

Biological Products; COVID-19; Inflammatory Bowel Diseases; Veterans; Biological Products/adverse effects; Biological Therapy; Cohort Studies; Humans; Inflammatory Bowel Diseases/drug therapy; Inflammatory Bowel Diseases/epidemiology; Pandemics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Veterans / Biological Products / Inflammatory Bowel Diseases / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Gastroenterology Year: 2021 Document Type: Article Affiliation country: J.gastro.2020.07.017

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google